Resmed Overview
Resmed (RMD) has a ROE of 23.13%, above the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow23.13%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for RMD is 23.13%. That is above the Healthcare sector average of 21.67%. Investors often review this figure alongside Resmed's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, RMD currently prints 23.13% for ROE, while the sector average sits near 21.67%. That is roughly 6.8% above the sector mean. Large gaps often invite a closer look at Resmed's growth, margins, and balance sheet.
Return on Equity shows how effectively Resmed converts resources into returns. At 23.13%, RMD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting RMD's ROE (23.13%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Resmed's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
